炭疽疫苗吸附佐剂用于暴露后预防的免疫原性、安全性和批次一致性:一项3期随机双盲试验
这项3期随机双盲试验在3689名18至65岁健康成人中比较CYFENDUS(AV7909,吸附佐剂炭疽疫苗)与BioThrax的免疫原性和安全性。CYFENDUS按0、2周肌内接种,BioThrax按0、2、4周皮下接种。第64天免疫原性达到预设成功标准,CYFENDUS对BioThrax非劣效且具统计学优效,疫苗耐受良好。
要点
- CYFENDUS在第64天达到保护性免疫水平,TNA NF50≥0.56比例95%CI下限高于40%。
- CYFENDUS对BioThrax非劣效且统计学优效,TNA NF50≥0.29比例差95%CI为20.0–29.2%。
- 最常见不良事件为注射部位相关,多为1级或2级严重程度。
核心结论
- CYFENDUS在健康成人中诱导保护性免疫应答,对BioThrax非劣效且统计学优效,耐受良好。
研究设计与样本
- 3期随机双盲试验纳入3689名18至65岁健康成人,随机接受CYFENDUS(0、2周肌内)或BioThrax(0、2、4周皮下)。
主要发现
- 第64天CYFENDUS组TNA NF50≥0.56的比例95%CI为64.5%–68.1%,下限高于预设≥40%标准。
- CYFENDUS与BioThrax组TNA NF50≥0.29比例差的95%CI为20.0%–29.2%,下限大于预设非劣效界值-15%且达统计学优效。
- 最常见不良事件为注射部位相关,多数报告的症状性反应性和不良事件为1级或2级。
关键数值与推荐
- 主要免疫原性终点预设成功标准:TNA NF50≥0.56比例95%CI下限≥40%。
- 非劣效 criterion:TNA NF50≥0.29比例差95%CI下限>-15%。
临床怎么用
- 疑似或确诊炭疽芽孢杆菌暴露后,CYFENDUS可按0、2周肌内接种方案与推荐抗菌药物联合用于暴露后预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This double-blinded randomized Phase 3 study evaluated the immunogenicity and safety of CYFENDUS® vaccine (AV7909; Anthrax Vaccine Adsorbed, Adjuvanted) to support licensure for post-exposure prophylaxis following suspected or confirmed Bacillus anthracis exposure when administered with the recommended antibacterial drugs. METHODS: Healthy adult participants (n = 3689) aged 18 to 65 were randomized to receive CYFENDUS vaccination (intramuscularly at 0, 2 weeks) or BioThrax® (Anthrax Vaccine Absorbed) [subcutaneously at 0, 2, 4 weeks]. Immunogenicity at Day 64 (seven weeks after the last CYFENDUS vaccine dose; five weeks after the last BioThrax vaccine dose) was evaluated using a 50 % neutralizing factor (NF50) threshold of protective immunogenicity generated by a toxin neutralizing antibody (TNA) assay, and by evaluating non-inferiority of CYFENDUS to BioThrax vaccination. Safety was assessed by physical exams, vital signs, solicited local injection site and systemic reactogenicity, and unsolicited adverse events (AEs). RESULTS: The prospectively defined success criteria were met for the primary immunogenicity endpoints. The lower bound of the two-sided 95 % confidence interval (CI) for the proportion of CYFENDUS participants with TNA NF50 ≥ 0.56 was above the pre-defined criterion of ≥40 % (95 % CI: 64.5 %, 68.1 %). The lower bound of the two-sided 95 % CI of the difference in the proportion of participants with TNA NF50 ≥ 0.29 in the CYFENDUS versus the BioThrax vaccine group was greater than the pre-defined non-inferiority criterion of -15 % as well as demonstrating statistical superiority (95 % CI: 20.0, 29.2 %), a closed hypothesis test supported by regulatory agencies in well-controlled clinical trials. The most common adverse events (AE) were injection site-related; most reported solicited reactogenicities and AEs were either Grade 1 or 2 severity. CONCLUSIONS: The study met the pre-defined endpoint criteria, demonstrating protective level of immune response and non-inferiority of CYFENDUS to BioThrax vaccination. The CYFENDUS vaccine was well-tolerated in healthy adults. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03877926.
引用
- Drobic B, Akintunde G, Kim J, et al. Immunogenicity, safety, and lot consistency of the anthrax vaccine adsorbed, adjuvanted for post-exposure prophylaxis of anthrax in healthy adults: A phase 3, randomized, double-blind trial. Vaccine. 2025. PMID: 41401704. doi:10.1016/j.vaccine.2025.128068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。